newsfilter
← Latest News
GlobeNewswire·

Theriva™ Biologics Announces Reverse Stock Split

  • Theriva Biologics, Inc. announced a reverse stock split at a ratio of one (1) new share for every thirty (30) existing shares.
  • The split becomes effective at 11:59 p.m. Eastern Time on December 1, 2026, with split-adjusted trading commencing on December 2, 2026.
  • The Board of Directors authorized the split on November 13, 2026, without shareholder approval pursuant to Nevada state law.
  • Outstanding shares will decrease from 45,892,668 to approximately 1,529,756, while authorized shares will drop from 350,000,000 to 11,666,666.
  • The primary purpose of the split is to ensure compliance with NYSE American per share price requirements.
  • Stockholders holding fractional shares will automatically receive an additional fractional share to round up to the next whole share.
  • Proportionate adjustments will be made to outstanding warrants, stock options, and equity incentive plan reserves.
  • The stock ticker remains "TOVX" on the NYSE American, but the CUSIP number will change to 87164U607.
  • Shareholders with physical certificates must follow instructions from transfer agent Equiniti Trust Company for exchange, while "street name" holders require no action.
  • Theriva Biologics is a clinical-stage company developing VCN-01, an oncolytic adenovirus candidate for treating cancer.
Company
Theriva Biologics, Inc.
Keywords
NYSE:TOVX, Theriva Biologics, Inc.